# US 11,439,315 B2 · MRI T1W and T2W combined features for detecting neurodegeneration > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,439,315 B2 - Document ID: US11439315B2 - Status: Granted - Kind: B2 - Application number: 16/970,029 - Filed: 2018-11-13 - Published: 2021-04-15 - Granted: 2022-09-13 - Earliest claimed: 2018-03-05 - Assignees: The Penn State Research Foundation - Applicants: The Penn State Research Foundation - Inventors: Guangwei Du; Xuemei Huang; Mechelle Lewis - Web page: https://patentgrep.com/patent/US11439315B2 ## CPC - A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging - A61B 5/4064: {Evaluating the brain (for intracranial pressure A61B5/031; for cerebral blood gases A61B5/14553; using EEG A61B5/369)} - A61B 5/4082: {Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette} - G01R 33/5601: {involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent} - G01R 33/5602: {by filtering or weighting based on different relaxation times within the sample, e.g. T1 weighting using an inversion pulse} - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12) ## Abstract Embodiments can relate to a method for detecting a physiological condition by generating a Magnetic Resonance Image (MRI) contrast image comprising a T1 weighted (T1W) image/T2 weighted (T2W) ratio. Embodiments can further include using the T1W/T2W ratio to identify changes in substantia nigra pars compacta within a region of the brain. ## Claims ### Claim 1 A method of identifying neurodegeneration, comprising: generating at least one first magnetic resonance image (MRI) contrast image of tissue of a first specimen belonging to a cohort, the at least one first MRI contrast image comprising a first T1-weighted (T1W)/T2-weighted (T2W) ratio map, the first T1W/T2W ratio map comprising a plurality of T1W/T2W ratios for a plurality of anatomical locations of the first specimen's tissue, the cohort comprising a group of specimen's having a form of neurodegeneration; designating the at least one first Mill contrast image as a Mill contrast image template for the cohort; generating a second Mill contrast image of tissue of a second specimen not being part of the cohort but suspected of having the form of neurodegeneration, the second MRI contrast image comprising a second T1W/T2W ratio map, the second T1W/T2W ratio map comprising a plurality of T1W/T2W ratios for a plurality of anatomical locations of the second specimen's tissue; defining a region within the Mill contrast image template having predetermined neurodegeneration-related change of substantia nigra pars compacta (SNc) associated with the form of neurodegeneration and extracting a T1W/T2W ratio intensity from the region; comparing a T1W/T2W ratio intensity from the second T1W/T2W ratio map to the extracted T1W/T2W ratio intensity to identify a change of SNc in the second specimen's tissue; and determining that the change of SNc in the second specimen's tissue is representative of the predetermined neurodegeneration-related change of SNc of the cohort. ### Claim 2 (depends on 1) The method recited in claim 1, wherein the at least one first MRI contrast image comprises a plurality of first Mill contrast images, wherein an individual first Mill contrast image is generated for each cohort of a plurality of cohorts. ### Claim 3 (depends on 2) The method recited in claim 2, wherein the form of neurodegeneration is a form of Parkinson's Disease (PD). ### Claim 4 (depends on 3) The method recited in claim 3, wherein: the plurality of cohorts comprises: a first cohort comprising specimens having no form of PD; a second cohort comprising specimens having Hoehn Yahr stage I PD; and a third cohort comprising specimens having Hoehn Yahr stage II PD. ### Claim 5 (depends on 1) The method recited in claim 1, wherein: the at least one first MRI contrast image comprises a plurality of T1W images and T2W images for a plurality of anatomical locations of the first specimen's tissue, wherein a T1W image for an anatomical location is co-registered with a T2W image for the same anatomical location, and the first T1W/T2W ratio map is generated by dividing each T1W image signal intensity by its co-registered T2W image signal intensity; and the second Mill contrast image comprises a plurality of T1W images and T2W images for a plurality of anatomical locations of the second specimen's tissue, wherein a T1W image for an anatomical location is co-registered with a T2W image for the same anatomical location, and the second T1W/T2W ratio map is generated by dividing each T1W image signal intensity by its co-registered T2W image signal intensity. ### Claim 6 (depends on 1) The method recited in claim 1, wherein the predetermined neurodegeneration-related change of SNc identifies a loss of dopaminerigic neurons. ### Claim 7 (depends on 1) The method recited in claim 1, wherein: the first specimen's tissue comprises a midbrain region of the first specimen; and the second specimen's tissue comprises a midbrain region of the second specimen. ### Claim 8 (depends on 1) The method recited in claim 1, wherein the comparing step comprises voxel-based analysis. ### Claim 9 (depends on 1) The method recited in claim 1, wherein the comparing step comprises region-of-interest based analysis. ### Claim 10 (depends on 5) The method recited in claim 5, further comprising normalizing the plurality of T1W images and T2W images of the at least one first MRI contrast image and normalizing the plurality of T1W images and T2W images of the second MRI contrast image. ### Claim 11 A method of identifying a physiological condition, comprising: generating a magnetic resonance image (MRI) contrast image template of tissue of a first specimen belonging to a cohort, the Mill contrast image template comprising a first T1-weighted (T1W)/T2-weighted (T2W) ratio map, the first T1W/T2W ratio map comprising a plurality of T1W/T2W ratios for a plurality of anatomical locations of the first specimen's tissue; generating a Mill contrast image of tissue of a second specimen not being part of the cohort but suspected of having a physiological condition associated with the cohort, the Mill contrast image comprising a second T1W/T2W ratio map, the second T1W/T2W ratio map comprising a plurality of T1W/T2W ratios for a plurality of anatomical locations of the second specimen's tissue; and comparing T1W/T2W ratio intensities of the first T1W/T2W ratio map to T1W/T2W ratio intensities of the second T1W/T2W ratio map to identify changes in substantia nigra pars compacta (SNc) in the second specimen's tissue as compared to the first specimen's tissue that are at or exceed a pre-selected threshold value to detect the physiological condition. ### Claim 12 (depends on 11) The method recited in claim 11, wherein the physiological condition comprises neurodegeneration. ### Claim 13 (depends on 12) The method recited in claim 12, wherein the neurodegeneration is a form of Parkinson's Disease (PD). ### Claim 14 (depends on 11) The method recited in claim 11, wherein the changes in SNc identifies a loss of dopaminerigic neurons. ### Claim 15 (depends on 11) The method recited in claim 11, wherein the generating of the MRI contrast image of the tissue of the second specimen comprises scanning the second specimen with an Mill scanner. ### Claim 16 (depends on 11) The method recited in claim 11, wherein the comparing step comprises at least one of voxel-based analysis and region-of-interest based analysis. ### Claim 17 A medical device apparatus comprising: a computer device having a processor connected to a non-transitory computer readable medium, the computer device configured to receive magnetic resonance image data generated by a magnetic resonance imaging scanner; the computer device configured to co-register each T1W image of the magnetic resonance image data for a patient with each T2W image of the same anatomical location of the patient and divide each T1W image signal intensity by its corresponding co-registered T2W image signal intensity to generate at least one T1W/T2W ratio map; and the computer device configured to compare T1W/T2W ratio intensities of a first T1W/T2W ratio map to T1W/T2W ratio intensities of a second T1W/T2W ratio map of a pre-selected first cohort to identify changes in substantia nigra pars compacta (SNc) that are at or exceed a first pre-selected threshold value to detect a physiological condition of the patient. ### Claim 18 (depends on 17) The medical device apparatus of claim 17, wherein the physiological condition is a form of Parkinson's Disease (PD). ### Claim 19 (depends on 18) The medical device apparatus of claim 18, wherein the computer device is also configured to compare T1W/T2W ratio intensities of the first T1W/T2W ratio map to T1W/T2W ratio intensities of a third T1W/T2W ratio map of a pre-selected second cohort to identify changes in substantia nigra pars compacta (SNc) that are at or exceed a second pre-selected threshold value to detect a physiological condition of the patient. ### Claim 20 (depends on 19) The medical device apparatus of claim 19, wherein the computer device is also configured to compare T1W/T2W ratio intensities of the first T1W/T2W ratio map to T1W/T2W ratio intensities of a fourth T1W/T2W ratio map of a pre-selected third cohort to identify changes in substantia nigra pars compacta (SNc) that are at or exceed a third pre-selected threshold value to detect a physiological condition of the patient; and wherein the medical device apparatus also includes the Mill scanner.